|
|
Synthetic Blood Products: Market and TechnologyPublished by: PJB Publications USA Inc. Published: Oct. 1, 2000 - 138 Pages Table of Contents1. Executive Summary 1.1 Introduction 1.2 Methodology 1.3 Scope 2. Overview 2.1 Composition of Blood 2.2 Blood Transfusion 2.2.1 Brief History 2.2.2 Statistics 2.2.3 Transfusion-Transmitted Risks 2.2.3.1 Viruses 2.2.3.2 Parasites 2.2.3.3 Prion Diseases 2.3 Synthetic Blood 2.3.1 Developmental History of Synthetic Blood 2.3.2 Advantages of Synthetic Blood 2.3.3 Applications for Synthetic Blood 3. Synthetic Blood Products Currently Available 3.1 Overview of Products Currently Available 3.2 Blood Volume Expanders 3.3 Recombinant Products to Treat Hemophilia 3.3.1 Hemophilia: Facts and Figures 3.3.2 von Willebrand Disease (vWD) 3.3.3 Recombinant Technology 4. Synthetic Blood Products in Phase III Clinical Trials 4.1 Overview 4.2 Perfluorocarbon Technology 4.2.1 Oxygent: Only Perfluorocarbon Product in Late-Stage Clinical Trials 4.2.2 Clinical Trial Status 4.3 Modified Hemoglobin Technology 4.3.1 Hemolink 4.3.2 Hemopure 4.3.3 PolyHeme 5. Synthetic Blood Products in Research and Early-Stage Clinical Trials 5.1 Overview 5.2 Perfluorocarbon-Based Products 5.2.1 Oxycyte 5.2.2 Perftoran 5.2.3 PHER-O2 Molecule 5.2.4 Perfluoropentane 5.3 Modified Hemoglobin-Based Products 5.3.1 Recombinant Hemoglobin 5.3.2 PEG Technology 5.3.3 SNO-Hb Therapeutic Agents 5.4 Synthetic Platelets 5.4.1 Synthocytes 5.5 Recombinant Albumin 5.5.1 Transgenic Technology 5.5.2 Albrec (rHSA) 5.6 The Frontier of Blood Substitute Research 5.6.1 Genetically Engineered Plants 5.6.2 Nanotechnology 6. The Market For Synthetic Blood Products 6.1 Blood Volume Expanders 6.1.1 Major Competitors 6.1.2 Issues and Trends 6.2 The Market for Recombinant Coagulation Factor Products 6.2.1 Products and Competitors 6.2.2 Competitive Threats to the Recombinant Products Market 6.2.2.1 Transgenic Coagulation Factors 6.2.2.2 Gene Therapy 6.3 Market for Synthetic Blood Products 6.3.1 The U.S. Red Blood Cell Transfusion Market 6.3.2 Applications for the First Synthetic Blood Products 6.3.3 First Generation Synthetic Blood Products: Market Forecast 6.3.4 Factors That May Affect Future Sales of Synthetic Blood Products 7. Company Profiles 7.1 Alliance Pharmaceutical Corp. 7.2 Baxter Healthcare Inc. 7.3 Bayer Corporation 74 Biopure Corp. 7.5 BioTime Corp. 7.6 Enzon, Inc. 7.7 Genetics Institute 7.8 Genzyme Transgenics Corporation 7.9 Hemosol Inc. 7.10 Northfield Laboratories 7.11 Novo Nordisk 7.12 Perftoran Company 7.13 Sanguine Corp. 7.14 SONUS Pharmaceutical Inc. 7.15 Synthetic Blood International, Inc. 7.16 Quadrant Healthcare plc 7.17 Welfide Corp. 8. Corporate Directory AbstractThis report reviews the commercial prospects for synthetic blood product technologies, including market size, market growth potential, technological issues and other factors. It also presents the major innovators who are poised to revolutionize the nature of the blood supply. Products in several specific blood functions are covered, including volume expanders, recombinant hemophilia treatments, tissue oxygenation technologies, synthetic platelets and recombinant albumin. The study reviews each new technology in turn, describing the state of the clinical approval process, profiling the companies developing the technology and analyzing the emerging market opportunities. Combined, these synthetic blood products promise to comprise the largest pharmaceutical market sector ever.Please Note: Theta requires that, for PDF orders, clients sign a confidentiality agreement prior to fulfillment of PDF email delivery. Get Full Details About This Report >> |
|
|||
|
About MarketResearch.com
|
||||